Question explored with the scientific record
what. are the side effects of losartan
The short version: losartan works by lowering blood pressure, and most of its side effects are the predictable consequences of that mechanism, not exotic toxicities.
Losartan is an angiotensin receptor blocker. It lowers blood pressure by blocking a hormone that constricts blood vessels. The main risks follow from that: blood pressure that drops too far, especially when standing up, and a rise in potassium. In the RENAAL trial of 1,513 people with diabetic kidney disease, losartan roughly tripled the odds of potassium climbing above 5.0 mmol/L, and about 1 in 10 people on it reached 5.5 or higher [5]. That matters because higher potassium tracked with worse kidney outcomes in the same analysis [5]. The drug also raises bradykinin, a peptide that dilates vessels, which is the mechanism behind the rare but serious side effect of angioedema, swelling of the lips and throat [1, 2]. One case report describes a 74-year-old man on losartan who developed lip swelling after adding naproxen, so NSAIDs deserve caution in combination [1].
The evidence base here is mostly mechanistic and observational. The bradykinin finding comes from a small human study of hypertensive patients [2]. The potassium data comes from a post hoc analysis of a manufacturer-funded trial, which means it was not designed to answer the safety question directly [5]. No long-term safety registry with a true unexposed comparison group appears in this retrieval. What the records do show is that losartan protects kidney function in several animal models and small human studies, reducing proteinuria and fibrosis [7, 11, 13]. One in vitro study found losartan caused no DNA damage in human lymphocytes, unlike some older blood pressure drugs [10]. A rat study raised a specific concern: losartan-induced low blood pressure was linked to memory deficits and tau protein changes in the brain, though this has not been confirmed in humans [15].
| Side effect | What the evidence shows |
|---|---|
| High potassium | About 38 in 100 on losartan reached 5.0+ mmol/L vs placebo; 11 in 100 reached 5.5+ [5] |
| Angioedema | Rare; mechanism via bradykinin increase; case report with NSAID trigger [1, 2] |
| Low blood pressure | Expected effect; one study withdrawal for symptomatic hypotension [20] |
| Kidney protection | Reduced proteinuria and fibrosis in animal models and small trials [7, 11, 13] |
| DNA damage | None found in human lymphocytes in vitro [10] |
My call: losartan is a reasonably well-characterized drug whose main risks are potassium elevation and blood pressure drops, both manageable with monitoring, but the long-term safety picture is thinner than the marketing suggests. Confidence: moderate.
Sources used 9
-
Recurrent angioedema after naproxen use in a patient stabilized with losartan
This case study presents a 74-year-old male who experienced recurrent angioedema after using naproxen while stabilized on losartan, highlighting the potential risks of NSAID use in patients on angiotensin receptor blockers.
DOI: 10.1016/j.anai.2014.08.022 -
Losartan Increases Bradykinin Levels in Hypertensive Humans
In hypertensive humans, the AT1 receptor blocker losartan increases arterial bradykinin levels and alters angiotensin peptide metabolism, suggesting a class effect that may contribute to therapeutic actions and angioedema risk.
DOI: 10.1161/01.cir.0000153269.07762.3b -
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Post hoc analysis of the RENAAL trial showing that losartan raises serum potassium, higher potassium is associated with worse renal outcomes, and adjusting for potassium enhances the apparent renoprotective effect of losartan, suggesting potassium management may augment ARB bene…
DOI: 10.1007/s00125-010-1922-6 -
Advanced IgA nephropathy with impaired renal function benefits from losartan treatment in rats
In a rat model of advanced IgA nephropathy with impaired renal function induced by SEB plus 5/6 nephrectomy, losartan treatment attenuated renal injury by reducing proteinuria and serum creatinine/BUN, decreasing IgA deposition and tubulointerstitial fibrosis, and downregulating…
DOI: 10.3109/0886022X.2013.794686 -
Cytotoxic and genotoxic effects of antihypertensives distributed in Brazil by social programs: Are they safe?
An in vitro assessment of cytotoxic and genotoxic effects of six antihypertensive drugs distributed in Brazil's social program on human lymphocytes and macrophages, revealing dose-dependent DNA damage for captopril, enalapril, and hydrochlorothiazide while losartan and propranol…
DOI: 10.1016/j.etap.2018.08.005 -
Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats
Mizoribine and losartan mitigate cyclosporine A-induced nephrotoxicity and glomerular growth impairment in young rats by reducing inflammation and fibrosis and preserving glomerular size.
DOI: 10.1038/srep22374 -
Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis
This study investigates the effects of low doses of losartan and enalapril, both alone and in combination, on proteinuria and kidney function in patients with primary glomerulonephritis over a 9-month period, finding that while both drugs reduce proteinuria, the combination ther…
DOI: 10.1080/00365590410015687 -
Losartan-Induced Hypotension Leads to Tau Hyperphosphorylation and Memory Deficit
Chronic losartan-induced hypotension in adult rats causes oxidative stress with PP2A inactivation, tau hyperphosphorylation, dendritic spine loss, CREB activation, and memory deficits, while propranolol-induced hypotension yields milder effects with no significant cognitive impa…
DOI: 10.3233/JAD-131679 -
The antiproteinuric effect of losartan is systemic blood pressure dependent
This randomized longitudinal study in proteinuric, non-diabetic renal disease shows that losartan’s antiproteinuric effect is largely driven by its BP-lowering action, with no strong evidence for a non-haemodynamic mechanism and no substantial difference between 50 mg vs 100 mg …
DOI: 10.1093/ndt/gfg315